Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial
The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...
Medical Xpress23d
Scientists determine why some patients don't respond well to wet macular degeneration treatment: New drug may bridge gap
A study from researchers at Wilmer Eye Institute, Johns Hopkins Medicine explains not only why some patients with wet age-related macular degeneration ... an experimental drug could be used ...
RNA editing is the next frontier in gene therapy—here's what you need to know
The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA ...
MarketWatch3h
Outlook Therapeutics Trial of Eye Disease Treatment Misses Key Endpoint
The biopharmaceutical company said the trial of ONS-5010 to treat wet age-related macular degeneration didn't meet the pre ... in a special protocol assessment the U.S. Food and Drug Administration.
Hosted on MSN1mon
Common diabetes drug shows promise for treating macular degeneration
Age-related macular degeneration (AMD ... some researchers have turned their attention to metformin—a drug better known for treating type 2 diabetes—because of promising data on its overall ...